Acellera’s mission is to accelerate the transition to rational, computerized drug discovery via simulations and machine learning.
In order to fulfill this vision, we work with our customers by becoming a key technology partner, boosting their discovery workflow with the most innovative solutions. Science, research, innovation and development are the core values of our company.
Acellera is devoted to bringing state-of-the-art technologies to drug discovery. Founded in 2006, we were one of the first companies worldwide to leverage the use of novel accelerator processor technology (GPU) for molecular dynamics.
We developed the first online platform for drug design based on deep learning and are now leading the introduction of machine learning techniques into the drug discovery pipeline.
ACEMD released - MD on GPU
Fitness of MD for Drug Discovery:
The Benzamidine -Trypsin example
Introduction of HTMD: Lowering the Barrier to build, Run and analyze MD
Launch of PlayMolecule - Machine Learning for Drug Design
OpenMM collaboration - Chan-Zuckerberg Initiative support
First private PlayMolecule instance
Today, our software ACEMD has over 700 citations, and KDeep and Deepsite are among the most cited papers in the field of ML applied to drug discovery.